Skip to main content
. 2023 Aug 29;14:1206953. doi: 10.3389/fimmu.2023.1206953

Figure 1.

Figure 1

CD3+HLADR+ cell frequencies before ICI therapy significantly predict OS, response and toxicity. (A, B) High CD3+HLADR+ cell frequencies in the peripheral blood at baseline indicate a worse response to ICI therapy at 3 and 6 month (p3months=0.051, p6months=0.008). (C, D) High baseline CD3+HLADR+ cell frequencies indicate poor 3 and 6 months survival under immune checkpoint blockade (p3months=0.067, p6months=0.003). (E) Baseline CD3+HLADR+ cell frequencies are higher among patients who develop immune related adverse events (IRAE) under ICI therapy (p=0.043). (F) Overall survival is lower in patients who do not develop any grade of IRAE (median OS: 151 days vs. “not reached”, p<0.001). (G) Baseline frequencies of CD3+HLADR+ cells do not differ between patients experiencing IRAE ≥ grade 3 and patients who do not (p=0.595). *: significant (p<0.05); **: highly significant (p<0.01); n.s.: not significant (p>0.05).